NDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROCKLATAN is a fixed-dose ophthalmic combination of netarsudil and latanoprost indicated for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It combines a Rho kinase inhibitor with a prostaglandin analog to provide dual mechanism IOP reduction via trabecular and uveoscleral outflow pathways.
$146MPart D
PeakStable
7.4 years to LOEROCKLATAN remains at peak lifecycle with 273K+ annual claims and $146M Part D spending, supporting sustained commercial and medical affairs staffing.
Mechanism of Action
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
Started Oct 2026
13 enrolled
Open Angle Glaucoma (OAG)Glaucoma
Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
Started Jul 2026
50 enrolled
Ocular HypertensionSuspect Glaucoma
Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
Started Jun 2026
50 enrolled
GlaucomaOcular Hypertension
Rocklatan Retinal Perfusion OCT Study
Started Jan 2026
30 enrolled
Glaucoma
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Started Nov 2025
30 enrolled
Open Angle GlaucomaOcular Hypertension
Worked on ROCKLATAN at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.